Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tamibarotene by Syros Pharmaceuticals for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Tamibarotene is under clinical development by Syros Pharmaceuticals and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
Tamibarotene by Syros Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Tamibarotene is under clinical development by Syros Pharmaceuticals and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
Tamibarotene by Syros Pharmaceuticals for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Tamibarotene is under clinical development by Syros Pharmaceuticals and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Tamibarotene by Toko Pharmaceutical Industries for Polycystic Kidney Disease: Likelihood of Approval
Tamibarotene is under clinical development by Toko Pharmaceutical Industries and currently in Phase II for Polycystic Kidney Disease. According to...